

DAFTAR PUSTAKA

- Anagnostis, S., Khehra, N., & Parmar, M. S. (2023). Chlorpromazine. *Encyclopedia of Toxicology, Fourth Edition: Volume 1-9, 2*, V2-995-V2-1002. <https://doi.org/10.1016/B978-0-12-824315-2.00648-5>
- Anggita Ratnaningtyas, M., Indrawati, F., Ilmu Kesehatan Masyarakat, J., Ilmu Keolahragaan, F., & Negeri Semarang, U. (2023). Karakteristik Ibu Hamil dengan Kejadian Kehamilan Risiko Tinggi. *HIGEIA (Journal of Public Health Research and Development)*, 7(3), 334–344. <https://doi.org/10.15294/HIGEIA.V7I3.64147>
- Aronson, J. K., & Ferner, R. E. (2017). Unlicensed and off-label uses of medicines: definitions and clarification of terminology. *British journal of clinical pharmacology*, 83(12), 2615–2625. <https://doi.org/10.1111/BCP.13394>
- Ayad, M., & Costantine, M. M. (2015). Epidemiology of medications use in pregnancy. *Seminars in perinatology*, 39(7), 508–511. <https://doi.org/10.1053/J.SEMPERI.2015.08.002>
- Badan Pengawas Obat dan Makanan Republik Indonesia. (2017). *Informatorium Obat Nasional Indonesia* (Cetakan Tahun 2017). Badan POM RI.
- Berghella, V. (2017). Obstetric Evidence Based Guidelines, Third Edition. Dalam *Obstetric Evidence Based Guidelines, Third Edition*. <https://doi.org/10.1201/9781315200903>
- Betts, J. G., Desaix, P., Johnson, E., Johnson, J. E., Korol, O., Kruse, D., Poe, B., Wise, J., Womble, M. D., & Young, K. A. (2013). *Anatomy & Physiology* (1st Edition). OpenStax. https://books.google.com/books/about/Anatomy_and_Physiology.html?hl=id&id=dvVgngEACAAJ
- Chong, Y. S., Su, L. L., & Arulkumaran, S. (2004). Misoprostol: a quarter century of use, abuse, and creative misuse. *Obstetrical & gynecological survey*, 59(2), 128–140. <https://doi.org/10.1097/01.OGX.0000109168.83489.66>

- Coordinator, Mortality, N. S. C. on M., Medicine, N. S. C. on F., National Specialized Commission on Childbirth, P. and A. C., Law, N. S. C. on S. V. and P. I. P. for by, Care, N. S. C. on A., Pregnancy, N. S. C. on H.-R., Emergency, N. S. C. on U. and, Appreciation, N. S. C. on P. D. and, & Revision. (2023). Misoprostol use in obstetrics: Number 6 – June 2023. *RBGO Gynecology & Obstetrics*, 45(6), 356. <https://doi.org/10.1055/S-0043-1770931>
- Da Graça Krupa, F., Cecatti, J. G., De Castro Surita, F. G., Milanez, H. M. B. P., & Parpinelli, M. Â. (2005). Misoprostol versus expectant management in premature rupture of membranes at term. *BJOG : an international journal of obstetrics and gynaecology*, 112(9), 1284–1290. <https://doi.org/10.1111/J.1471-0528.2005.00700.X>
- Daud, A. N. A., Bergman, J. E. H., Bakker, M. K., Wang, H., De Walle, H. E. K., Plösch, T., & Wilffert, B. (2014). Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. *Pharmacogenomics*, 15(7), 1029–1041. <https://doi.org/10.2217/PGS.14.62>
- Day, R. (2013). Off-label prescribing. *Australian Prescriber*, 36(6), 182–183. <https://doi.org/10.18773/AUSTPRESCR.2013.075>
- Dong, C., & Cumpston, K. L. (2023). Diphenhydramine. *Encyclopedia of Toxicology, Fourth Edition: Volume 1-9, 3*, V3-857-V3-861. <https://doi.org/10.1016/B978-0-12-824315-2.00822-8>
- Enis Rosuliana, N., Aryanti, D., Triguna, Y., Keperawatan, J., & Kemenkes Tasikmlaya, P. (2022). Analisis Usia Gestasi Ibu Melahirkan dengan Berat badan Bayi Baru Lahir di Rumah Sakit. *Media Informasi*, 18(2), 67–72. <https://doi.org/10.37160/BMI.V18I2.40>
- Food and Drug Administration. (2014). Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. *Federal register*, 79(233).

- Gazarian, M., Kelly, M., McPhee, J. R., Gaudins, L. V., Ward, R. L., & Campbell, T. J. (2006). Off-label use of medicines: Consensus recommendations for evaluating appropriateness. *Medical Journal of Australia*, 185(10). <https://doi.org/10.5694/j.1326-5377.2006.tb00689.x>
- Goločorbin Kon, S., Iliković, I., & Mikov, M. (2015). Reasons for and frequency of off-label drug use. *Medicinski pregled*, 68(1–2), 35–40. <https://doi.org/10.2298/MPNS1502035G>
- Griddine, A., & Bush, J. S. (2023). Ondansetron. *xPharm: The Comprehensive Pharmacology Reference*, 1–6. <https://doi.org/10.1016/B978-008055232-3.62327-X>
- Guttmacher, A. E., Maddox, Y. T., & Spong, C. Y. (2014). The Human Placenta Project: placental structure, development, and function in real time. *Placenta*, 35(5), 303–304. <https://doi.org/10.1016/J.PLACENTA.2014.02.012>
- Haas, D. M., Daggy, J., Flannery, K. M., Dorr, M. L., Bonsack, C., Bhamidipalli, S. S., Pierson, R. C., Lathrop, A., Towns, R., Ngo, N., Head, A., Morgan, S., & Quinney, S. K. (2019). A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. *American journal of obstetrics and gynecology*, 221(3), 259.e1-259.e16. <https://doi.org/10.1016/J.AJOG.2019.04.037>
- Herring, C., McManus, A., & Weeks, A. (2010). Off-label prescribing during pregnancy in the UK: an analysis of 18 000 prescriptions in Liverpool Women's Hospital. *International Journal of Pharmacy Practice*, 18(4). <https://doi.org/10.1211/ijpp.18.04.0007>
- Hines, R. N. (2013). Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children. *International Journal of Pharmaceutics*, 452(1–2), 3–7. <https://doi.org/10.1016/J.IJPHARM.2012.05.079>

- IDI. (2017). Panduan Praktik Klinis Bagi Dokter di Fasilitas Pelayanan Kesehatan Primer. *Ministeri Kesehatan Republik Indonesia*.
- Kaandorp, S. P., Goddijn, M., van der Post, J. A. M., Hutten, B. A., Verhoeve, H. R., Hamulyák, K., Mol, B. W., Folkeringa, N., Nahujs, M., Papatonis, D. N. M., Büller, H. R., van der Veen, F., & Middeldorp, S. (2010). Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. *The New England journal of medicine*, 362(17), 1586–1596. <https://doi.org/10.1056/NEJMOA1000641>
- Ke, A. B., Rostami-Hodjegan, A., Zhao, P., & Unadkat, J. D. (2014). Pharmacometrics in Pregnancy: An Unmet Need. <https://doi.org/10.1146/annurev-pharmtox-011613-140009>, 54, 53–69. <https://doi.org/10.1146/ANNUREV-PHARMTOX-011613-140009>
- Kerr, R. S., Kumar, N., Williams, M. J., Cuthbert, A., Aflaifel, N., Haas, D. M., & Weeks, A. D. (2021). Low-dose oral misoprostol for induction of labour. *The Cochrane database of systematic reviews*, 6(6). <https://doi.org/10.1002/14651858.CD014484>
- Komarjah, N., Setiawandari, & Waroh, Y. K. (2023). Determinan Kejadian Persalinan Sectio Caesarea (Sc) Di Rsud Syamrabu Bangkalan. *Prosiding Seminar Nasional Hasil Riset dan Pengabdian*.
- Krugh, M., Patel, P., & Maani, C. V. (2024a). Misoprostol. *xPharm: The Comprehensive Pharmacology Reference*, 1–5. <https://doi.org/10.1016/B978-008055232-3.62195-6>
- Krugh, M., Patel, P., & Maani, C. V. (2024b). Misoprostol. *xPharm: The Comprehensive Pharmacology Reference*, 1–5. <https://doi.org/10.1016/B978-008055232-3.62195-6>
- Kurtz, I., Kraut, J., Ornekian, V., & Nguyen, M. K. (2008). Acid-base analysis: A critique of the Stewart and bicarbonate-centered approaches. *American Journal of Physiology - Renal Physiology*, 294(5), 1009–1031.

<https://doi.org/10.1152/AJPRENAL.00475.2007/ASSET/IMAGES/LARGE/ZH20030850580003.JPEG>

Kushtagi, P. (2006). A re-look at the duration of human pregnancy. *Singapore Med J*, 47(12), 1044–1048.

Lemeshow, S., Hosmer, D. W., Janelle, K., & Stephen, K. L. (1990). *Adequacy of Sample Size in Health Studies*. John Wiley & Sons Ltd.

Leveno, K. J., Spong, C. Y., Dashe, J. S., Casey, B. M., Hoffman, B. L., Cunningham, F. G., & Bloom, S. L. (2018). *Williams Obstetrics* (25th Edition). McGraw-Hill Education.

Meng, M., Zhou, Q., Lei, W., Tian, M., Wang, P., Liu, Y., Sun, Y., Chen, Y., & Li, Q. (2022). Recommendations on Off-Label Drug Use in Pediatric Guidelines. *Frontiers in Pharmacology*, 13, 892574. <https://doi.org/10.3389/FPHAR.2022.892574/BIBTEX>

Meyer, A., Feraut, M., Drouin, J., Carbonnel, F., & Weill, A. (2021). Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010–2018. *PLoS ONE*, 16(1). <https://doi.org/10.1371/JOURNAL.PONE.0245854>

Middleton, P., Shepherd, E., Flenady, V., McBain, R. D., & Crowther, C. A. (2017). Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). *The Cochrane database of systematic reviews*, 1(1). <https://doi.org/10.1002/14651858.CD005302.PUB3>

Morris, J. L., Winikoff, B., Dabash, R., Weeks, A., Faundes, A., Gemzell-Danielsson, K., Kapp, N., Castleman, L., Kim, C., Ho, P. C., & Visser, G. H. A. (2017). FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. *International Journal of Gynecology & Obstetrics*, 138(3), 363–366. <https://doi.org/10.1002/ijgo.12181>

Mutmainah, D. A. (2016). *Skrining Obat-Obat Off-Label pada Pasien Obstetri dan Ginekologi di Rumah Sakit Wijayakusuma Purwokerto*. Universitas Muhammadiyah Purwokerto.

- NIGHTINGALE, S. L. (2003). Off-Label Use of Prescription Drugs. *American Family Physician*, 68(3), 425–427.
<https://www.aafp.org/pubs/afp/issues/2003/0801/p425.html>
- Ningsih, S. W. (2020). *Kajian Penggunaan Obat Off-Label pada Pasien Ibu Hamil di Instalasi Rawat Inap Rumah Sakit Islam Jakarta Sukapura Periode 2019*. Universitas Muhammadiyah Prof. DR. Hamka.
- Ochoa-Bernal, M. A., & Fazleabas, A. T. (2020). Physiologic Events of Embryo Implantation and Decidualization in Human and Non-Human Primates. *International Journal of Molecular Sciences* 2020, Vol. 21, Page 1973, 21(6), 1973. <https://doi.org/10.3390/IJMS21061973>
- Oshikoya, K. A., Wharton, G. T., Avant, D., Van Driest, S. L., Fenn, N. E., Lardieri, A., Doe, E., Sood, B. G., Taketomo, C., Lieu, P., Yen, L., & McMahon, A. W. (2019). Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review. *Pediatric Drugs*, 21(1), 47–58. <https://doi.org/10.1007/S40272-018-0318-9/FIGURES/1>
- Papalia, D. E., Olds, S. Wendkos., & Feldman, R. Duskin. (2009). *Human Development*. McGraw-Hill Education.
- Pascual, Z. N., & Langaker, M. D. (2023). Physiology, Pregnancy. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK559304/>
- Paumgartten, F. J. R., & de Oliveira, A. C. A. X. (2020). Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. *Ciência & Saúde Coletiva*, 25(9), 3413–3419. <https://doi.org/10.1590/1413-81232020259.16792020>
- Pinontoan, V. M., & Tombokan, S. (2015). Hubungan Umur dan Paritas Ibu dengan Kejadian Bayi Berat Lahir Rendah. *JIDAN (Jurnal Ilmiah Bidan)*, 3(1), 20–25. <https://doi.org/10.47718/JIB.V3I1.355>

- Pratiwi, E. A. (2015). *Penggunaan Obat Off-Label pada Pasien Hamil di Instalasi Rawat Inap dan Gawat Darurat Kebidanan-Kandungan RSUP Fatmawati Periode Maret 2015*. Universitas Indonesia.
- Rayburn, W. F., & Farmer, K. C. (1997). Off-label prescribing during pregnancy. *Obstetrics and Gynecology Clinics of North America*, 24(3), 471–478. [https://doi.org/10.1016/S0889-8545\(05\)70317-X](https://doi.org/10.1016/S0889-8545(05)70317-X)
- Rubinchik-Stern, M., & Eyal, S. (2012). Drug interactions at the human placenta: What is the evidence? *Frontiers in Pharmacology*, 3 JUL, 27396. <https://doi.org/10.3389/FPHAR.2012.00126/BIBTEX>
- Rusz, C. M., Ősz, B. E., Jitcă, G., Miklos, A., Bătrînu, M. G., & Imre, S. (2021). Off-label medication: From a simple concept to complex practical aspects. *International Journal of Environmental Research and Public Health*, 18(19). <https://doi.org/10.3390/ijerph181910447>
- Sachdeva, P., Patel, B. G., & Patel, B. K. (2009). Drug Use in Pregnancy; a Point to Ponder! *Indian Journal of Pharmaceutical Sciences*, 71(1), 1. <https://doi.org/10.4103/0250-474X.51941>
- Sanchez-Ramos, L., Levine, L. D., Sciscione, A. C., Mozurkewich, E. L., Ramsey, P. S., Adair, C. D., Kaunitz, A. M., & McKinney, J. A. (2024). Methods for the induction of labor: efficacy and safety. *American Journal of Obstetrics and Gynecology*, 230(3), S669–S695. <https://doi.org/10.1016/J.AJOG.2023.02.009/ATTACHMENT/349B882D-0356-4976-85BA-FABB86645BE9/MMC5.MP4>
- Shah, S., & van Geijn, H. (2007). Managing the risks of off-licence prescribing in pregnancy. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 130(2). <https://doi.org/10.1016/j.ejogrb.2006.08.022>
- Sharma, R., Kapoor, B., & Verma, U. (2006). Drug utilization pattern during pregnancy in North India. *Indian Journal of Medical Sciences*, 60(7), 277–287. <https://doi.org/10.4103/0019-5359.26602>

- Sheffield, J. S., Siegel, D., Mirochnick, M., Heine, R. P., Nguyen, C., Bergman, K. L., Savic, R. M., Long, J., Dooley, K. E., & Nesin, M. (2014). Designing drug trials: considerations for pregnant women. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 59 Suppl 7(Suppl 7), S437–S444. <https://doi.org/10.1093/CID/CIU709>
- Shen, S., Yang, J., Chen, Y., Xie, J., Huang, Y., Lin, W., & Liao, Y. (2022). Original research: Off-label indications of aspirin in gynaecology and obstetrics outpatients at two Chinese tertiary care hospitals: a retrospective cross-sectional study. *BMJ Open*, 12(2), 50702. <https://doi.org/10.1136/BMJOPEN-2021-050702>
- Smith, J., Fox, K., & Clark, S. (2023). *Nausea and vomiting of pregnancy: treatment and outcome*. UptoDate.
- Susanti, I. (2021). EVALUASI KELENGKAPAN RESEP UNTUK MENCEGAH MEDICATION ERROR. *JOHC*, 2.
- Thorpe, P. G., Gilboa, S. M., Hernandez-Diaz, S., Lind, J., Cragan, J. D., Briggs, G., Kweder, S., Friedman, J. M., Mitchell, A. A., & Honein, M. A. (2013). Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. *Pharmacoepidemiology and Drug Safety*, 22(9), 1013–1018. <https://doi.org/10.1002/PDS.3495>
- Tukayo, B. L. A., Sunderland, B., Parsons, R., & Czarniak, P. (2020). High prevalence of off-label and unlicensed paediatric prescribing in a hospital in Indonesia during the period Aug.—Oct. 2014. *PLoS ONE*, 15(1). <https://doi.org/10.1371/JOURNAL.PONE.0227687>
- Turner, J. V., Agatonovic-Kustrn, S., & Ward, H. (2015). Off-label use of misoprostol in gynaecology. *Facts, Views & Vision in ObGyn*, 7(4), 261. [/pmc/articles/PMC5058416/](https://pubmed.ncbi.nlm.nih.gov/26158416/)
- Vauzelle, C., Beghin, D., Cournot, M. P., & Elefant, E. (2013). Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up

- study. *Reproductive toxicology* (Elmsford, N.Y.), 36, 98–103.
<https://doi.org/10.1016/J.REPROTOX.2012.11.009>
- Ward, R. M., & Varner, M. W. (2019). Principles of Pharmacokinetics in the Pregnant Woman and Fetus. *Clinics in perinatology*, 46(2), 383–398.
<https://doi.org/10.1016/J.CLP.2019.02.014>
- Weeks, A., Alfrevic, Z., Faúndes, A., Hofmeyr, G. J., Safar, P., & Wing, D. (2007). Misoprostol for induction of labor with a live fetus. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 99 Suppl 2(SUPPL. 2).
<https://doi.org/10.1016/J.IJGO.2007.09.011>
- Wesley, B. D., Sewell, C. A., Chang, C. Y., Hatfield, K. P., & Nguyen, C. P. (2021). Prescription medications for use in pregnancy—perspective from the US Food and Drug Administration. *American Journal of Obstetrics and Gynecology*, 225(1), 21–32. <https://doi.org/10.1016/j.ajog.2021.02.032>
- Wibowo, M. I. N. A., Sugiri, M. P., Arrista, B., & Setiawan, D. (2021). Penggunaan Off-Label Misoprostol Pada Pasien Obstetri-Ginekologi Di Rumah Sakit Swasta Kab. Banyumas. *Jurnal Sains Farmasi & Klinis*, 8(1), 9–18.
<https://doi.org/10.25077/JSFK.8.1.9-18.2021>
- Wing, D. A., Brown, R., Plante, L. A., Miller, H., Rugarn, O., & Powers, B. L. (2013). Misoprostol vaginal insert and time to vaginal delivery: a randomized controlled trial. *Obstetrics and gynecology*, 122(2 Pt 1), 201–209.
<https://doi.org/10.1097/AOG.0B013E31829A2DD6>
- Yurniati, Y., & Resky, R. (2017). *HUBUNGAN PENYULIT PERSALINAN DENGAN KEJADIAN SECTIO CAESAREA DI RSUD SAYANG RAKYAT PERIODE JANUARI-MEI 2017*. 2(2), 125–133.
<https://jurnal.uit.ac.id/MedBid/article/view/87>
- Zeteroğlu, Ş., Engin-Üstün, Y., Üstün, Y., Güvercinçi, M., Şahin, G., & Kamaci, M. (2006). A prospective randomized study comparing misoprostol and oxytocin for

premature rupture of membranes at term. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*, 19(5), 283–287.
<https://doi.org/10.1080/14767050600589807>